Goal 3: Advance Translational Research

Develop biomarker panel to predict CVD risk in -omics era

There is a need to utilize the vast data generated in -omics research to develop biomarker panels for better prediction of cardiovascular disease (CVD) risks. •Cardiovascular diseases develop over decades and different panels of markers may be required for different stages •Lead molecules as potential biomarkers need to be selected by a panel of experts •Standard procedures about sample preparation, data acquisition, ...more »

Submitted by (@nhlbiforumadministrator)

Voting

7 net votes
14 up votes
7 down votes
Active

Goal 2: Reduce Human Disease

Heterogeneity in Asthma Phenotypes

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Asthma appears to be due to heterogenous etiologies.  To better characterize the various phenotypes and potential etiologies, it would be important to create more epidemiologic and biomarker focused databases, which could ...more »

Submitted by (@wheeze)

Voting

-12 net votes
6 up votes
18 down votes
Active

Goal 3: Advance Translational Research

Maximizing Previous Investment in Existing Cohorts

Everyone would like to see integration of genomic, metabolomic, epigenomic, proteomic, transcriptomic, etc. data analyzed in the context of clinical disease, environmental influences, and even end-organ effects (lung versus heart or blood as an example). Rarely can this occur on small cohorts, but rarely are funds available to take maximum use of existing large cohorts and the samples and information collected within ...more »

Submitted by (@nhlbiforumadministrator)

Voting

22 net votes
34 up votes
12 down votes
Active

Goal 3: Advance Translational Research

Tools to facilitate availability and safe use of innovative blood products and their analogs

Novel blood products are being developed based on innovative science (e.g., ex vivo manufactured RBC and platelets, and platelet and plasma derived hemostatic products). However, there is a significant lag in the development of appropriate tools and model systems, which poses a challenge when evaluating such products for regulatory approval.

Submitted by (@chintamani.atreya)

Voting

12 net votes
17 up votes
5 down votes
Active

Goal 1: Promote Human Health

Understanding Individual Differences in Responses to Sleep Loss

Individuals differ substantially in their physiological, health, behavioral and cognitive responses to sleep loss. Although these differences represent a trait, individuals who are vulnerable in one domain may be resilient in another - few systematic relationships between physiological, long-term health, cognitive and subjective responses to sleep loss have been found. Moreover, within a given domain, vulnerability to ...more »

Submitted by (@hvd000)

Voting

124 net votes
171 up votes
47 down votes
Active

Goal 2: Reduce Human Disease

Biomarkers and Response Predictors in Asthma

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Given the development of specific biologic therapy for asthma, what are the biomarkers and predictors of response that will allow clinicians to choose the best therapeutic combination of medications (biologic and otherwise) ...more »

Submitted by (@wheeze)

Voting

7 net votes
18 up votes
11 down votes
Active